Literature DB >> 26316639

Draft Genome Sequences of Two IMP-4-Producing Escherichia coli Sequence Type 131 Isolates in Australia.

Hanna E Sidjabat1, Jennifer Robson2, David L Paterson3.   

Abstract

We report the draft genome sequences of two unrelated cases of Escherichia coli sequence type 131 (ST131) possessing the carbapenemase gene blaIMP-4. The E. coli ST131 SN5 isolate also possessed blaSHV-12 and plasmid-mediated quinolone-resistance genes. Wider dissemination of blaIMP-4 may occur due to the blaIMP-4-carrying L/M or HI2 plasmids among E. coli ST131 isolates.
Copyright © 2015 Sidjabat et al.

Entities:  

Year:  2015        PMID: 26316639      PMCID: PMC4551883          DOI: 10.1128/genomeA.00983-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Carbapenem-resistant Enterobacteriaceae (CRE) are regarded as an urgent antibiotic resistance threat by the Centers for Disease Control and Prevention (CDC). In the United States, the most common CRE strains produce the KPC beta-lactamase (1). Geographic variations in the type of carbapenemase responsible for CRE exist. The dominance of IMP-4-producing Enterobacter cloacae were recently reported in Australia (2). HI2 and L/M plasmids were the two main types of plasmids harboring blaIMP-4 (2). Escherichia coli sequence type 131 (ST131) has been recognized as a highly successful extraintestinal clone of E. coli causing urinary tract infections and frequently associated with the production of the extended-spectrum beta-lactamase CTX-M-15 (3). Two carbapenemase-producing E. coli isolates were obtained from patients from two hospitals in Australia. E. coli CR48 and E. coli SN5 were isolated from urine of an elderly woman and from sputum of an elderly man, respectively. Both E. coli isolates were characterized for the genes responsible for the resistance to beta-lactam antibiotics, especially to carbapenems. Initially, both isolates were determined to possess blaIMP-4 by PCR and classified as E. coli ST131 by repetitive sequence-based PCR (repPCR) (DiversiLab, bioMérieux). The two E. coli isolates were subjected to whole-genome sequencing to characterize the antibiotic resistance and virulence properties of the isolates. Whole-genomic DNA of E. coli CR48 and SN5 was extracted and prepared using the Nextera XT DNA sample preparation kit and sequenced using the Illumina HiSeq 2000 as previously described (4). De novo assembly was performed using CLC Genomics Workbench version 7.5 (CLC Bio, Denmark). The draft genomes of CR48 and SN5 consisted of 5,184,875 and 5,219,367 bp, respectively. Contigs were initially annotated using RAST (http://rast.nmpdr.org). Sequence typing, antibiotic resistance mechanisms, and plasmid Inc types of E. coli were determined through http://www.genomicepidemiology.org. The genome data showed that both E. coli isolates were ST131. Both E. coli strains also possessed blaTEM-1B, sul1, and aac(3)-IId. Additionally, E. coli SN5 possessed blaSHV-12, blaOXA-1, qnrA1, and qnrB49. E. coli CR48 possessed L/M and FII. Plasmids HI2, HI2A, FII, I1, Col156, and FIB were determined in SN5. The blaIMP-4 gene was most likely located on the L/M and HI2 plasmids in CR48 and SN5, respectively. The annotation through RAST identified type 1 fimbriae fimA-H, virulence determinants relevant for urinary tract adhesion in both isolates (5). Fimbriae related to the protein secretion system were identified: htrE fimbriae cluster, stf fimbriae cluster, and colonization factor antigen I fimbriae (CFA/I fimbriae). In addition, fimbriae usher protein StcC was identified. Further, IncF conjugal transfer pili were identified. The cluster responsible for Curli production or type VIII secretion was identified. There were variations of the siderophore enterobactin, siderophore aerobactin, and other hemin transport systems for iron acquisition in the two isolates. The blaIMP-4 genes in CR48 and SN5 were both located in the integron class 1. The genetic context of CR48 was tnpA|intI1|blaIMP-4|qacG|aacA4|catB3|∆qacE|sul1|ISCR1. Two studies reported the occurrence of IMP-8-producing E. coli ST131 in Taiwan and IMP-4-producing E. coli ST131 in China (6, 7). These cases of IMP-4-producing E. coli ST131 in Australia highlight potential further dissemination of blaIMP-4 among uropathogenic E. coli.

Nucleotide sequence accession numbers.

This project is registered as BioProject number PRJNA281568 and BioSample numbers SAMN03798494 (E. coli ST131 CR48) and SAMN03491847 (E. coli ST131 SN5). The draft genomes of IMP-4-producing E. coli ST131 CR48 and SN5 have been deposited in GenBank under the accession numbers LFXT00000000 and LFXU00000000, respectively.
  7 in total

1.  Emergence of the IMP-8 metallo-β-lactamase in the Escherichia coli ST131 clone in Taiwan.

Authors:  Jing-Jou Yan; Le-Hsi Tsai; Jiunn-Jong Wu
Journal:  Int J Antimicrob Agents       Date:  2012-07-11       Impact factor: 5.283

2.  Molecular epidemiology of carbapenemase-producing Escherichia coli and the prevalence of ST131 subclone H30 in Shanghai, China.

Authors:  F Zhang; D Zhu; L Xie; X Guo; Y Ni; J Sun
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-03-11       Impact factor: 3.267

Review 3.  The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae.

Authors:  Amy J Mathers; Gisele Peirano; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 4.  Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain.

Authors:  Benjamin A Rogers; Hanna E Sidjabat; David L Paterson
Journal:  J Antimicrob Chemother       Date:  2010-11-16       Impact factor: 5.790

5.  Dominance of IMP-4-producing enterobacter cloacae among carbapenemase-producing Enterobacteriaceae in Australia.

Authors:  Hanna E Sidjabat; Nicola Townell; Graeme R Nimmo; Narelle M George; Jennifer Robson; Renu Vohra; Louise Davis; Claire Heney; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

6.  Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms.

Authors:  Makrina Totsika; Scott A Beatson; Sohinee Sarkar; Minh-Duy Phan; Nicola K Petty; Nathan Bachmann; Marek Szubert; Hanna E Sidjabat; David L Paterson; Mathew Upton; Mark A Schembri
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

7.  Draft Genome Sequence of NDM-5-Producing Escherichia coli Sequence Type 648 and Genetic Context of blaNDM-5 in Australia.

Authors:  Alexander M Wailan; David L Paterson; Michael Caffery; David Sowden; Hanna E Sidjabat
Journal:  Genome Announc       Date:  2015-04-09
  7 in total
  3 in total

1.  First Report of blaIMP-14 on a Plasmid Harboring Multiple Drug Resistance Genes in Escherichia coli Sequence Type 131.

Authors:  Nicole Stoesser; Anna E Sheppard; Gisele Peirano; Robert P Sebra; Tarah Lynch; Luke W Anson; Andrew Kasarskis; Mary R Motyl; Derrick W Crook; Johann D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  Isolation and plasmid characterization of carbapenemase (IMP-4) producing Salmonella enterica Typhimurium from cats.

Authors:  Sam Abraham; Mark O'Dea; Darren J Trott; Rebecca J Abraham; David Hughes; Stanley Pang; Genevieve McKew; Elaine Y L Cheong; John Merlino; Sugiyono Saputra; Richard Malik; Thomas Gottlieb
Journal:  Sci Rep       Date:  2016-10-21       Impact factor: 4.379

Review 3.  Extended-spectrum β-lactamase-producing and carbapenemase-producing Enterobacteriaceae.

Authors:  Hayley Wilson; M Estée Török
Journal:  Microb Genom       Date:  2018-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.